Covaxin Phase 2-3 clinical trials for 2-18 age group to begin in June, youngest participant 2-year-old

The Phase 2-3 clinical trials of Covaxin, which has been approved by the DCGI for the age group of 2 to 18 years, will begin in June, as per reliable sources.

The Phase 2 and 3 clinical trials of Bharat Biotech’s Covaxin in the age group of 2 to 18 years will begin in June, sources in the Hyderabad-based vaccine maker have said. Covaxin, which has been indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR), is being used on adults in India's ongoing Covid-19 vaccination drive. Earlier this month, Bharat Biotech was granted permission to conduct the Phase 2/3 clinical trial of Covaxin in the age group of 2 to 18 years. Sources at Bharat Biotech told India Today that the Phase 2/3 trails for children will begin in June. Dosing will begin in June and end by mid-July. The youngest child recruited for the clinical study is a two-year-old, Bharat Biotech sources added. Coronavirus Updates on May 24